Search | Clinical Trials Finder

Conditions: Immune Thrombocytopenia, Blood Platelet Disorder, Hematologic Diseases, Purpura, Thrombocytopenic, Purpura, Blood Coagulation Disorder, Thrombotic Microangiopathies, Hemorrhagic Disorders, Autoimmune Diseases, Immune System Diseases, Hemorrhage, Pathologic Processes, Skin Manifestations, Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, Primary Immune Thrombocytopenia, ITP - Immune Thrombocytopenia
Interventions: HMPL-523; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: Irvine, California • Georgetown, Delaware • Bethesda, Maryland + 7 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ITP, Immune Thrombocytopenia
Interventions: Fostamatinib; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Romiplostim; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more

Conditions: Thrombocytopenia
Interventions: Daclizumab; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immune Thrombocytopenia (ITP)
Interventions: Placebo, Lusutrombopag; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Immune Thrombocytopenia
Interventions: rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Clovis, California • New Orleans, Louisiana • Boston, Massachusetts + 5 more

Conditions: Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Immune Thrombocytopenia (ITP)
Interventions: Pirtobrutinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 8 more

Conditions: Purpura, Thrombocytopaenic, Idiopathic
Interventions: eltrombopag; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Gainesville, Florida • Orlando, Florida

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag, Placebo; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Long Beach, California • Orange, California + 18 more

Conditions: Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP)
Interventions: RAY121; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 11
States / cities: Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Avatrombopag, Standard of care; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Watertown, South Dakota

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more

Conditions: Immune Thrombocytopenic Purpura
Interventions: BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more

Conditions: Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions: sirolimus; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Immune Thrombocytopenia
Interventions: Eltrombopag, Romiplostim, healthy controls; Drug · Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Immune Thrombocytopenia
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Months to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Interventions: KZR-616; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more

Conditions: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
Interventions: ianalumab, thrombopoietin receptor agonist (TPO-RA); Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Margate, Florida • Hinsdale, Illinois

Conditions: Chronic Immune Thrombocytopenia
Interventions: Panzyga; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Sacramento, California • Minneapolis, Minnesota • Rochester, Minnesota + 5 more

Conditions: Immune Thrombocytopenia
Interventions: Acetaminophen and Diphenhydramine Only Product; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Daclizumab to Treat Chronic Immune Thrombocytopenia

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

Sirolimus for Autoimmune Disease of Blood Cells

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Post IVIG Medication in Children With Immune Thrombocytopenia